02 Jul 2024
18:00 CEST |
IPSEN |
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 26 - 2024
|
20103015 Pharmaceuticals |
Share history |
02 Jul 2024
18:00 CEST |
IPSEN |
IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024
|
20103015 Pharmaceuticals |
Share history |
02 Jul 2024
07:00 CEST |
IPSEN |
Ipsen étend sa collaboration et son accord de licence pour le développement de Cabometyx® dans le traitement des tumeurs neuroendocrines avancées sur la base des résultats positifs de l’essai de Phase III CABINET
|
20103015 Pharmaceuticals |
- |
02 Jul 2024
07:00 CEST |
IPSEN |
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
|
20103015 Pharmaceuticals |
- |
25 Jun 2024
18:00 CEST |
IPSEN |
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 25 - 2024
|
20103015 Pharmaceuticals |
Share history |
25 Jun 2024
18:00 CEST |
IPSEN |
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024
|
20103015 Pharmaceuticals |
Share history |
18 Jun 2024
18:00 CEST |
IPSEN |
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024
|
20103015 Pharmaceuticals |
Share history |
18 Jun 2024
18:00 CEST |
IPSEN |
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 24 - 2024
|
20103015 Pharmaceuticals |
Share history |
11 Jun 2024
18:00 CEST |
IPSEN |
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024
|
20103015 Pharmaceuticals |
Share history |
11 Jun 2024
18:00 CEST |
IPSEN |
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 23 - 2024
|
20103015 Pharmaceuticals |
Share history |
10 Jun 2024
22:54 CEST |
IPSEN |
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
|
20103015 Pharmaceuticals |
- |
10 Jun 2024
22:54 CEST |
IPSEN |
Le médicament Iqirvo® d’Ipsen obtient l’approbation de la FDA via une procédure accélérée comme traitement PPAR premier de sa classe thérapeutique pour la cholangite biliaire primitive
|
20103015 Pharmaceuticals |
- |
07 Jun 2024
07:00 CEST |
IPSEN |
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
|
20103015 Pharmaceuticals |
- |
07 Jun 2024
07:00 CEST |
IPSEN |
Ipsen et Marengo Therapeutics annoncent la conclusion d’un second partenariat stratégique afin de faire progresser les actifs « T-Cell Engager » de précision de la plateforme TriSTAR de Marengo
|
20103015 Pharmaceuticals |
- |
06 Jun 2024
18:00 CEST |
IPSEN |
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
|
20103015 Pharmaceuticals |
Share history |
06 Jun 2024
18:00 CEST |
IPSEN |
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Share history |
06 Jun 2024
14:30 CEST |
IPSEN |
Ipsen nomme Josep Catllà, en qualité de Vice-Président Exécutif, Chief Corporate Affairs Officer
|
20103015 Pharmaceuticals |
- |
06 Jun 2024
14:30 CEST |
IPSEN |
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
|
20103015 Pharmaceuticals |
- |
05 Jun 2024
08:00 CEST |
IPSEN |
Ipsen présente de nouvelles données sur l’efficacité à long terme d’elafibranor et la qualité de vie liée aux démangeaisons chez les patients atteints de cholangite biliaire primitive
|
20103015 Pharmaceuticals |
- |
05 Jun 2024
08:00 CEST |
IPSEN |
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis
|
20103015 Pharmaceuticals |
- |
03 Jun 2024
07:00 CEST |
IPSEN |
Ipsen lance un programme de rachat d’actions pour couvrir son programme d’attribution d’actions gratuites aux salariés
|
20103015 Pharmaceuticals |
Other subject |
03 Jun 2024
07:00 CEST |
IPSEN |
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan
|
20103015 Pharmaceuticals |
Other subject |
30 May 2024
18:15 CEST |
IPSEN |
Ipsen announces the launch of an employee shareholding plan
|
20103015 Pharmaceuticals |
Other subject |
30 May 2024
18:15 CEST |
IPSEN |
Ipsen annonce le lancement d'une opération d’actionnariat salarié
|
20103015 Pharmaceuticals |
Other subject |
28 May 2024
18:00 CEST |
IPSEN |
Annual General Meeting of Ipsen S.A. held on 28 May 2024
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |
28 May 2024
18:00 CEST |
IPSEN |
Assemblée Générale Annuelle d’Ipsen S.A. du 28 mai 2024
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |
28 May 2024
07:00 CEST |
IPSEN |
Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024
|
20103015 Pharmaceuticals |
Share history |
28 May 2024
07:00 CEST |
IPSEN |
Descriptif du cadre réglementaire du programme de rachat d’actions soumis par le Conseil d’administration à l’approbation de l’Assemblée Générale Annuelle des actionnaires d’Ipsen S.A. du 28 mai 2024
|
20103015 Pharmaceuticals |
Share history |
07 May 2024
14:55 CEST |
IPSEN |
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |
07 May 2024
14:55 CEST |
IPSEN |
IPSEN SA. - Modalités de mise à disposition et de consultation des documents préparatoires à l’Assemblée Générale Mixte du 28 mai 2024
|
20103015 Pharmaceuticals |
General meeting / Board Meeting |
06 May 2024
18:00 CEST |
IPSEN |
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
|
20103015 Pharmaceuticals |
Share history |
06 May 2024
18:00 CEST |
IPSEN |
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Share history |
02 May 2024
07:30 CEST |
IPSEN |
Ipsen nomme Keira Driansky, en qualité de Vice-Présidente Exécutive, et Présidente Amérique du Nord
|
20103015 Pharmaceuticals |
Other subject |
02 May 2024
07:30 CEST |
IPSEN |
Ipsen appoints Keira Driansky as EVP, President of North America
|
20103015 Pharmaceuticals |
Other subject |
24 Apr 2024
07:00 CEST |
IPSEN |
Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2024
|
20103015 Pharmaceuticals |
Commercial results |
24 Apr 2024
07:00 CEST |
IPSEN |
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
|
20103015 Pharmaceuticals |
Commercial results |
22 Apr 2024
07:00 CEST |
IPSEN |
Ipsen et Skyhawk Therapeutics annoncent la signature d'un accord de collaboration de recherche visant le ciblage d’ARN dans les maladies neurologiques rares
|
20103015 Pharmaceuticals |
Alliances and agreements |
22 Apr 2024
07:00 CEST |
IPSEN |
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
|
20103015 Pharmaceuticals |
Alliances and agreements |
17 Apr 2024
18:00 CEST |
IPSEN |
Ipsen publishes its 2023 Universal Registration Document
|
20103015 Pharmaceuticals |
Corporate life |
17 Apr 2024
18:00 CEST |
IPSEN |
Ipsen publie son Document d’enregistrement universel 2023
|
20103015 Pharmaceuticals |
Corporate life |
08 Apr 2024
18:00 CEST |
IPSEN |
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
|
20103015 Pharmaceuticals |
Share history |
08 Apr 2024
18:00 CEST |
IPSEN |
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Share history |
02 Apr 2024
07:00 CEST |
IPSEN |
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
|
20103015 Pharmaceuticals |
Alliances and agreements |
02 Apr 2024
07:00 CEST |
IPSEN |
Ipsen et Sutro Biopharma annoncent la signature d'un accord exclusif de licence mondiale pour un conjugué anticorps-petite molecule ciblant les tumeurs solides
|
20103015 Pharmaceuticals |
Alliances and agreements |
07 Mar 2024
18:00 CET |
IPSEN |
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
|
20103015 Pharmaceuticals |
Share history |
07 Mar 2024
18:00 CET |
IPSEN |
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
|
20103015 Pharmaceuticals |
Share history |
15 Feb 2024
10:00 CET |
IPSEN |
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
|
20103015 Pharmaceuticals |
Sales |
15 Feb 2024
10:00 CET |
IPSEN |
Ipsen S.A. publie ses comptes consolidés 2023
|
20103015 Pharmaceuticals |
Sales |
13 Feb 2024
22:08 CET |
IPSEN |
Ipsen reçoit l’approbation de la FDA pour le schéma thérapeutique incluant Onivyde®, un potentiel nouveau traitement de référence en première ligne dans l'adénocarcinome du pancréas métastatique
|
20103015 Pharmaceuticals |
Products and services |
13 Feb 2024
22:08 CET |
IPSEN |
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
|
20103015 Pharmaceuticals |
Products and services |